PathAI logo

Variability in Liver Biopsy Assessment: Data from the Pegozafermin Phase 1b/2a Study in Subjects with Non-Alcoholic Steatohepatitis (NASH)

AASLD 2022

Study Background

The objective of the study was to assess the impact on histological endpoints in the Phase 1b/2a POC study of assessment by 4 individual expert NASH pathologists.
View Poster


Loomba et al.